GlassScriptPhysician profile
Mohammad S Haq
NPI 1811973183
$1,928.65
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $402 · 2021: $623 · 2022: $402 · 2023: $40.58 · 2024: $28.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $254.07 | 2019-2022 | |
| Lilly USA, LLC | $191.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.91 | 2019-2022 | |
| Abbott Laboratories | $150.72 | 2022-2024 | Tendril |
| Astrazeneca Pharmaceuticals LP | $142.31 | 2019-2022 | |
| Abbvie INC. | $138.14 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $116.19 | 2019-2022 | |
| Novo Nordisk INC | $108.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $90.66 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $77.09 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $75.01 | 2019-2020 | |
| Daiichi Sankyo INC. | $58.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $51.08 | 2020 | |
| Elutia, INC. | $47.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.02 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.94 | 2021 | |
| Pfizer INC. | $36.47 | 2021-2022 | |
| Atricure, INC. | $25.68 | 2022 | |
| Amgen INC. | $22.20 | 2021 | |
| Esperion Therapeutics, INC. | $16.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.90 | 2022 | |
| Mylan Specialty L.P. | $12.73 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.